Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
We recently published the latest in our occasional series of reports on the PD(L)1 space. The report analyses all the major clinical, regulatory and commercial milestones here since last September, focusing specifically on inhibitors of PD-(L)1, and considering novel immuno-oncology mechanisms only when these are part of a combination with anti-PD-(L)1.
It’s a fascinating part of the market, and to accompany this edition we’ve also recorded a podcast to enable us to delve into a few key areas in more detail. I was delighted to be joined in the podcast studio by Bertrand Delsuc, publisher of BioTech Radar and an essential follow on bioTwitter.
In the podcast, we talk through the latest Tigit catalysts, including what to expect next from Roche after the somewhat disappointing results of the Skyscraper-01 study. We also look at some of the latest developments around bispecifics and whether Astrazeneca really is on to something in this space.
Looking at the global market, we look at the difficulties that China-based developers are having in getting anything approved in the US, as well as considering if and how big pharma can start to make better use of the academic studies taking place. Finally, we consider the catalysts in subcutaneous formulations as the big players try to maintain revenues in the face of looming patent expiries for IV treatments.
We cover a lot in 30 minutes, and it’s a great way to catch up on the latest news in this market while you’re on the move. You can find the recording below, and if you’d like to read the full report you can access it here.